FGFR1 and urothelial carcinoma: Current evidence indicates that Erdafitinib exhibits certain therapeutic efficacy in the treatment of advanced solid tumors harboring FGFR1–4 mutations, with the most pronounced therapeutic effect observed in urothelial carcinoma.